EMBRAPII and Einstein issue a call for advanced therapies

The call for proposals intends to support startups and researchers looking to undertake projects in the field of advanced therapies

Editorial staff

The EMBRAPII Einstein Competence Center for Advanced Therapies (CCTA) and Eretz.bio—Hospital Israelita Albert Einstein’s startup hub—issued a call for applications from professionals looking to become entrepreneurs and startups that develop innovative solutions focused on advanced therapies.

The goal of the CCTA/Eretz.bio Call is to foster innovation and entrepreneurship, creating an environment favorable to developing technologies in this field.

The call is split into two separate programs:

Startup Creation and Attraction Program

Only one proposal will be selected;
Applicants must have a doctoral degree;
A proposal shall be submitted for an advanced therapy investigational medicinal product, with a TRL (technical readiness level) of 2 to 4;
Benefits include funding totaling R$750,000;
See the entire Call for Proposals HERE.

Entrepreneurship Program (PETA)

Up to four candidates will be selected;
Brazilians or foreigners residing in Brazil can participate;
A doctoral degree is required;
The program will offer free workshops and mentoring in innovation;
Benefits include networking with potential partners;
See the entire PETA Call for Proposals HERE.

Applications may be submitted until November 24^th. Applicants may only choose to participate in one of the two programs.

For more information and to apply, go to https://www.eretz.bio/ccta/

Advanced therapies and the CCTA

The EMBRAPII Einstein Competence Center for Advanced Therapies (CCTA), located at Hospital Israelita Albert Einstein since early 2024, aims to encourage the study of advanced therapies for innovative treatments for diseases that have yet to be remedied.

The main objective is to develop research that seeks cutting-edge solutions by potentiating or modifying the way human cells function.

The CCTA received R$15 million from the Brazilian Agency for Industrial Research and Innovation (EMBRAPII), from the Ministry of Health, and an additional R$15 million from the São Paulo State Research Foundation (FAPESP).

The development of advanced therapies includes creating therapeutic biological products from human cells and tissues manufactured or reformulated artificially, or based on recombinant DNA.

The aim is to repair, add, replace, or remove a genetic sequence or modify the expression of a gene, according to information from the National Health Surveillance Agency (ANVISA).

The CCTA seeks to act as a platform for basic and applied research, capable of generating knowledge about diseases that still lack satisfactory treatment, such as various types of cancer.

* This article may be republished online under the CC-BY-NC-ND Creative Commons license.
The text must not be edited and the author(s) and source (Science Arena) must be credited.